Pacira Pharmaceuticals (PCRX) reported that new data that show that patients receiving EXPAREL after hip replacement surgery had a reduction in opioid use,...
Pacira Pharmaceuticals' (PCRX) average rating among analysts is a hold, with an average price target of $55. Price: 41.63, Change: -1.41, Percent Change:...
Pacira Pharmaceuticals (PCRX) said a multinational phase 3 study supported the efficacy and safety of exparel as a single-injection interscalene brachial...
Pacira Pharmaceuticals Inc's (NASDAQ:PCRX, Recent Price: 47.97) Q2 quarterly and full year forecasted earnings estimates for the periods ending June 30,...
| Address | 5 Sylvan Way Parsippany, New Jersey 07054 |
| Phone | +1.973.254.3560 |
| Number of Employees | 518 |
| Recent SEC Filing | 06/13/2019 4 |
| Chairman, Chief Executive & Operating Officer | David M. Stack |
| Chief Financial Officer | Charles A. Reinhart |
| Vice President-Research & Development | Vladimir Kharitonov |
| Chief Medical Officer | Richard E. Scranton |
| Price Open | $43.92 |
| Previous Close | $44.08 |
| 52 Week Range | $30.00 - 55.00 |
| Market Capitalization | $1.8 B |
| Shares Outstanding | 41.3 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Other | Next Earnings Announcement | 08/01/2019 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 256.82 |
| Earnings per Share | $0.20 |
| Beta vs. S&P 500 | N/A |
| Revenue | $337.3 M |
| Net Profit Margin | 2.10% |
| Return on Equity | 2.40% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
